Skip to search formSkip to main contentSkip to account menu

GOPC/ROS1 Fusion Gene

Known as: ROS1/FIG Fusion Gene, FIG1-ROS1 Fusion Gene, FIG1/ROS1 Fusion Gene 
A fusion gene (~4.1 kb) that results from an interstitial deletion of 240 kb on 6q21 which fuses the first 7 exons of the GOPC gene to the last 9… 
National Institutes of Health

Related topics

Related topics

2 relations
GOPC/ROS1 Fusion ProteinTyrosine Phosphorylation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation
ALK rearrangements and ROS1 rearrangements are important therapeutic targets in non-small cell lung cancer (NSCLC). ALK-positive… 
2018
2018
Radiological findings of Fournier Gangrene: beyond subcutaneous emphysema
Poster: "ECR 2018 / C-0836 / Radiological findings of Fournier Gangrene: beyond subcutaneous emphysema" by: "C. Botia Gonzalez1… 
2018
2018
NTRK and ALK rearrangements in mesothelioma and lung carcinoid.
e20558Background: Gene rearrangements involving NTRK1, NTRK2, NTRK3, ROS1 and ALK result in oncogenic fusion proteins that have… 
2017
2017
Abstract 3168: Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor
The inevitable development of clinical drug resistance presents a common challenge for targeted cancer therapy. In non-small cell… 
2017
2017
Personalisierte Therapie des Lungenkarzinoms – Stand und Herausforderungen
Abstract So called „personalized therapy“ has revolutionized the care of non-small cell lung cancer (NSCLC). The discovery of… 
2017
2017
Données préliminaires de l’étude MATCH R
INTRODUCTION : L’ere des therapies ciblee a revolutionne la prise en charge therapeutique en oncologie. Cependant, les patients… 
2016
2016
Targeted Therapy und Precision Medicine
ZusammenfassungEin Anteil von 10 bis 15 % der nichtkleinzelligen Lungenkarzinome (NSCLC) proliferiert auf der Basis einer… 
2014
2014
11. ROS1 GENE REARRANGEMENTS IN NON-SMALL CELL LUNG CARCINOMA – A NEW GENETIC TARGET
Background: Targeted therapies aimed at specific molecular genetic alterations are revolutionising cancer treatment, particularly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)